Profil
Hui Ju Chan is currently the Chairman at PharmaDax (Guangzhou), Inc., Empax Pharma (Foshan) Inc., and Director at PharmaDax USA, Inc., Sandex Group Ltd., Fortune Tower Group Corp., and Shengqun Pharmaceutical Co., Ltd.
Additionally, Ms. Chan has been the President at PharmaDax Inc. since 2012.
Ms. Chan's education includes an undergraduate degree from National Taipei University of Technology and an MBA from Soochow University.
Postes actifs de Hui Ju Chan
| Sociétés | Poste | Début |
|---|---|---|
| PHARMADAX INC. | President | - |
| PharmaDax (Guangzhou), Inc. | Chairman | - |
| PharmaDax USA, Inc. | Director/Board Member | - |
| Sandex Group Ltd. | Director/Board Member | - |
| Fortune Tower Group Corp. | Director/Board Member | - |
| Empax Pharma (Foshan) Inc. | Chairman | - |
| Shengqun Pharmaceutical Co., Ltd. | Director/Board Member | - |
Formation de Hui Ju Chan
| National Taipei University of Technology | Undergraduate Degree |
| Soochow University /Taiwan/ | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
PharmaDax Inc.
 PharmaDax Inc. Pharmaceuticals: MajorHealth Technology PharmaDax Inc. engages in the development and marketing of generic dossiers. Its products include Glyburide, Quetiapine Fumarate ER, and Metoprolol Succinate ER tablets. The company was founded by Yi Pin Huang on March 21, 2008 and is headquartered in New Taipei, Taiwan. | Health Technology |
| PharmaDax USA, Inc. | |
| PharmaDax (Guangzhou), Inc. | |
| Sandex Group Ltd. | |
| Fortune Tower Group Corp. | |
| Empax Pharma (Foshan) Inc. | |
| Shengqun Pharmaceutical Co., Ltd. |
